Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6715762 | 0.90 | BRD4 (0.54) | KMT2AMEN1THRBPOLBALDH1A1 | |
| SCHEMBL6716791 | 0.88 | ALDH1A1 (0.49) | POLBALDH1A1LMNAALOX12HTT | |
| SCHEMBL6716842 | 0.87 | CYP1A2 (0.48) | POLBALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6716835 | 0.87 | CYP1A2 (0.48) | POLBALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL6716854 | 0.83 | ALDH1A1 (0.53) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL6719052 | 0.82 | ALDH1A1 (0.48) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL6719501 | 0.81 | MAPT (0.46) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL6717632 | 0.81 | ATM (0.47) | KMT2AMEN1THRBPOLBALDH1A1 | |
| SCHEMBL6723623 | 0.80 | POLB (0.51) | KMT2AMEN1POLBALDH1A1LMNA | |
| SCHEMBL6717139 | 0.79 | GAA (0.46) | KMT2AMEN1ALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | KMT2A 2020/4885MEN1 2933/4885THRB 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.